REPORT NUMBER 7

IMMUNOLOGIC INTERRELATIONSHIPS OF COLIFORM HEAT-LABILE AND HEAT-STABLE ENTEROTOXINS

Annual Report

Frederick A. Klipstein, M.D.

January, 1979

Supported by

U.S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND
Fort Detrick, Frederick, Maryland 21701

Contract No. DAMD 17-77-C-7032

University of Rochester
School of Medicine and Dentistry
Rochester, New York 14642

Approved for public release; distribution unlimited.

The findings in this report are not to be construed as an official Department of the Army position unless so designated by other authorized documents.
Immunologic Interrelationships of Coliform Heat-Labile and Heat-Stable Enterotoxins

Frederick A. Klipstein, M.D.

University of Rochester
School of Medicine and Dentistry
Rochester, New York 14642

DAMD 17-77-C-7832

January 15, 1979

13

Unclassified

Acute diarrhea / enterotoxins / immunization / cholera / coliform bacteria / Escherichia coli / Klebsiella pneumoniae / Enterobacter cloacae

The goal of these studies is the development of an immunization program to prevent diarrheal disease due to intestinal contamination by enterotoxigenic strains of coliform bacteria. We have demonstrated that (a) active immunization with a purified preparation of the polymyxin release form of Escherichia coli heat-labile enterotoxin yields protection against strains of this bacteria which produce this form of toxin; (b) the use of cimetidine renders the peroral route of immunization effective; and (c) peroral, but not parenteral, immunization affords extended protection.
FORWARD

This annual report describes research investigations conducted during the eleven month period between our previous annual report submitted on February 15, 1978 and January 15, 1979. A considerable portion of the work completed during this period has already been published and in those instances where such is the case, only a brief summary will be presented in this report.

The goals of our research during the second year of support (of which we are half-way through) were: (a) to produce a purified preparation of the polymyxin-release form of *E. coli* heat-labile toxin (LT); (b) to determine optimal routes and schedules for active immunization in rats using this material; and (c) to determine whether such immunization will protect against the water secretory effect of the toxin during in vivo colonization by a toxigenic strain in monocontaminated germfree rats. Projects a and b have been completed and project c is currently in progress.

1. PROTECTIVE EFFECT OF ACTIVE IMMUNIZATION WITH PURIFIED *Escherichia coli* HEAT-LABILE ENTEROTOXIN IN THE RAT.

Work on this project commenced in the spring of 1978 and the basic aspects of the investigation were completed by September. A report of the results has been accepted for publication in *Infection and Immunity* and is scheduled to appear in the March, 1979 issue. Copies of the manuscript were submitted with our quarterly report of September 1, 1978.

Basically, this study showed that short-term protection (ie. in rats challenged at one week after completion of boosting) can be achieved by immunization using either the parenteral or oral routes. Immunization exclusively by the parenteral route was highly effective, especially when boosting doses were given with Freund incomplete adjuvant. Parenteral priming followed by intestinal boosting was also effective when the boosts were given directly into the duodenum but not when they were given perorally even after the intragastric administration of bicarbonate. This led us to test the effect of ablating gastric secretions by the use of cimetidine administered intragastrically 2 hours before the peroral boost; this approach resulted in significant protection. We then found that the degree of protection is related to the dosage of the peroral boost: that a 250 μg weekly boost yields more protection than a 50 μg boost. Immunization exclusively by the peroral route (ie. priming and boosting) also yielded significant protection but only when the immunizing dosage was 250 μg per week. (We are currently evaluating whether even larger peroral immunizing dosages in the range of 500 μg will yield a greater degree of protection). In addition to challenge by toxin, which was conducted in all groups, rats immunized exclusively by the parenteral route or boosted perorally using cimetidine were challenged by the instillation of graded concentrations of viable organisms in ligated ileal loops. Both groups of rats were protected against a strain which produces just LT, as well as against a strain which produced LT and the heat-stable toxin (ST), but they were not protected against a strain which produces just ST (see attached Figure 1).

Since completing this initial work, we have continued to explore the optimum approach to immunization in terms of determining (a) which regimen yields the maximum immediate protection and (b) which regimen yields the maximum prolonged protection. In order to accomplish the first goal, we are in the process of reexamining the degree of protection in various immunization groups by extending the challenge concentration out to that dosage which will permit quantitation of the degree of protection.
by calculation of the protection index. We are also using this approach to
evaluate several different approaches to the various immunization schedules. To
cite one example, we questioned as to whether four weekly peroral boosts are
necessary after parenteral immunization to yield strong protection. The data ob-
tained, shown in Figure 2, indicate that they are; nevertheless, this does not
answer the next question which we will now consider; namely, whether biweekly
boosts using larger doses would be equally effective as four weekly boosts.

We have now completed an evaluation of extended protection following immuniza-
tion by two routes—intraperitoneal priming and boosting (IP/IP) and IP priming
and peroral boosting (IP/PO)—using schedules which had achieved strong short-term
protection. The results, shown in Figure 3, clearly indicate that peroral immunization
is required for prolonged protection. Protection in the IP/IP group was lost within
three weeks but it extended during the entire length of the period of study, three
months, in the IP/PO group. We will evaluate the length of protection in animals
immunized just by the peroral route commencing as soon as we have complete data
which identifies the optimum dosage for this approach; this information should be
available within the next two weeks.

(2) IMMUNOLOGIC PROTECTION DURING MONOCONTAMINATION BY TOXIGENIC
E. coli IN GERMFREE RATS.

Our initial observations concerning the suitability of the monocontaminated
ergfree rat as a model to investigate the pathophysiology of intestinal colonization
by toxigenic strains of coliform bacteria were described in last year's annual report.
This material is scheduled to be published in the February, 1979 issue of
GASTROENTEROLOGY.

By September, we felt that our basic studies concerning optimum approaches
to active immunization were sufficiently complete such that we could commence work
with the germfree model. To our consternation, we found that the sole vendor of
ergfree rats (Charles River Breeding Laboratory) was no longer able to provide
Sprague-Dawley rats, the strain used in our previous study. They were able to
provide Fisher strain rats; however, because these are a different strain with a
different plasma osmolality (requiring a modification of the perfusion fluid), we
were required to redo all our basic observations in noncontaminated animals and
those contaminated by a nontoxigenic strain of E. coli.

Preliminary pilot studies indicated that, just as we had found in our previous
study using the toxigenic strain of E. coli 334, intestinal colonization by strain
H-10407 (which is an ST/LT producer and has colonization factor) evokes jejunal
water secretion only after several weeks of colonization. For this reason, we focused
on ileal transport and have now completely defined the model in terms of contamination
by a nontoxigenic and a toxigenic strain (Figure 4). Bacterial colony counts in the
ileum have consistently ranged from $10^6$ to $10^8$ throughout the three week test period
in all contaminated animals. Next week we will commence immunization in a group of
10 germfree rats, and the following week in another group of 10, by the IP/PO
route using a peroral immunization dosage of 250 $\mu$g per week. One week after the
final boost (i.e. in late February), the immunized rats will be contaminated by
strain H-10407 and ileal water transport at two and three weeks after contamination
will be evaluated and compared to the values already obtained in unimmunized animals.
(3) ENTEROTOXIGENICITY OF ENTEROPATHOGENIC SEROTYPES OF *Escherichia coli* ISOLATED FROM INFANTS WITH EPIDEMIC DIARRHEA.

This study has been published (Infection Immunity 21:171, 1978) and abstract is appended to this report. Basically, the study showed that strains of enteropathogenic serotypes of *E. coli*, which on epidemiologic groups were clearly the causal agents responsible for outbreaks of infantile diarrhea but which did yield evidence of enterotoxicogenicity in conventional assay systems, do produce toxin-like material capable of inducing water secretion when perfused through the rat jejunum. The validity of these observations, and their significance for disease in humans, has been established by publication of work from another laboratory (Lancet 1:1119, 1978) which showed that these strains produce diarrheal disease when administered perorally to human volunteers.

(4) ENTEROTOXIGENICITY OF COLONIZING COLIFORM BACTERIA IN TROPICAL SPRUE AND BLIND-LOOP SYNDROME.

This study has been published (Lancet 2:342, 1978) and abstract is appended to this report. We were able to show that the predominant jejunal coliform flora isolated from 12 patients with tropical sprue consistently elaborated potent toxin material capable of altering intestinal water transport, whereas strains of similar species isolated from the small bowel of persons with the blind loop syndrome did not. This difference in the toxigenicity of these strains may account in part for the different intestinal response in these two disorders to contamination by coliform bacteria.

(5) COMPARISON OF ASSAY OF COLIFORM ENTEROTOXINS BY CONVENTIONAL TECHNIQUES VERSUS IN VIVO INTESTINAL PERFUSION.

These investigations were conducted in collaboration with Dr. Richard Guerrant of the University of Virginia Medical School and with the Center for Disease Control, Atlanta. They were undertaken to compare the results of various assay systems in detecting enterotoxin activity of strains of coliform bacteria. Thirty-six strains of coliform bacteria were tested for enterotoxicogenicity by conventional assays, including the Y-1 adrenal and Chinese hamster ovary cell assays for heat-labile (LT) toxin and the suckling mouse assay for heat-stable (ST) toxin, and for the ability of graded concentrations of ultrafiltrate toxin preparation to induce water secretion during in vivo perfusion in the rat jejunum. The ultrafiltrates of all 18 strains isolated from persons with diarrheal disease, including 7 of *Escherichia coli*, 7 of *Klebsiella pneumoniae*, and 4 of *Enterobacter cloacae* contained one (9 strains) or two (9 strains) toxin fractions, resembling either LT or ST in terms of apparent molecular weight and heat-lability characteristics, that induced water secretion at perfusion concentrations of 10 ng per ml or less. Five of the strains of *E. coli* and 2 of *Klebsiella* evoked a positive response in one or more of the conventional assay systems. None of 18 strains isolated from control sources produced similarly potent ultrafiltrate material and all were negative in the conventional assays. These results indicate that many strains of coliform bacteria, particularly of *Klebsiella* and *E. cloacae*, which elaborate potent toxin materials capable of inducing water secretion yield a negative response in conventional assay systems for enterotoxicogenicity. A report of this investigation has been submitted to INFECTION AND IMMUNITY.
SUMMARY

Our observations clearly establish the fact that active immunization using a purified form of polymyxin release *E. coli* heat-labile enterotoxin can produce strong immunological protection in rats against challenge by either this toxin itself or viable organisms which produce it. Immunologic protection can be achieved either by parenteral immunization or by peroral immunization if gastric secretion is ablated by the concomitant administration of cimetidine. Immunization by the parenteral approach alone yields only short-lived protection whereas immunization by a combined parenteral-peroral approach arouses prolonged protection. The protective effect of the latter approach during actual chronic intestinal contamination is currently being evaluated in germfree animals mono-contaminated by a toxigenic strain of *E. coli*. These observations strongly suggest the feasibility of, and may lead to, a program of prophylactic immunization in humans against diarrheal disease caused by intestinal contamination by LT-producing strains of *E. coli*.

In conducting the research described in this report, the investigators adhered to the "Guide for Laboratory Animal Facilities and Care," as promulgated by the Committee on the Guide for Laboratory Animal Resources, National Academy of Sciences National Research Council.
PUBLICATIONS


10. Klipstein FA, Guerrant RL, Wells JG, Short HB, Engert RF: Comparison of assay of coliform enterotoxins by conventional techniques versus in vivo intestinal perfusion. Submitted for publication
Protection Afforded by Immunization with E. coli LT Against Various Challenges

Values for the IP/PO route are for boosting at the 50 μg per week dosage.

FIGURE 1
RELATIONSHIP OF PROTECTION TO THE NUMBER OF WEEKLY PERORAL BOOSTS GIVEN AFTER PARENTERAL PRIMING (IP/PO)

FIGURE 2

SECRETORY RESPONSE (μC/cm)

TOXIN CHALLENGE (μg)
PROLONGED PROTECTION AFFORDED BY VARIOUS IMMUNIZATION ROUTES

% REDUCED SECRECTION AT ED50

WEEKS AFTER IMMUNIZATION

CHALLENGE

FIGURE 3
ILEAL WATER TRANSPORT FOLLOWING MONOCONTAMINATION WITH *E coli*

![Graph showing ileal water transport following monocontamination with E coli](image)

-0- WEEKS AFTER MONOCONTAMINATION

- GERM FREE
- NTG MONOCONTAMINATED
- CONVENTIONAL
- TOX (LT/ST) MONOCONTAMINATED

**FIGURE 4**
<table>
<thead>
<tr>
<th>Copies</th>
<th>Recipient</th>
</tr>
</thead>
</table>
| 12     | Director (ATTN: SGRD-UWZ-AG)  
Walter Reed Army Institute of Research  
Walter Reed Army Medical Center  
Washington, DC 20012 |
| 4      | HQDA (SGRD-SI)  
Fort Detrick  
Frederick, MD 21701 |
| 12     | Defense Documentation Center  
ATTN: DDC-DCA  
Cameron Station  
Alexandria, VA 22314 |
| 1      | Dean  
School of Medicine  
Uniformed Services University of the Health Sciences  
4301 Jones Bridge Road  
Bethesda, MD 20014 |
| 1      | Superintendent  
Academy of Health Sciences, US Army  
ATTN: AHS-COM  
Fort Sam Houston, TX 78234 |